Nothing Special   »   [go: up one dir, main page]

SG10201704616SA - Compositions and methods for modulating cell signaling - Google Patents

Compositions and methods for modulating cell signaling

Info

Publication number
SG10201704616SA
SG10201704616SA SG10201704616SA SG10201704616SA SG10201704616SA SG 10201704616S A SG10201704616S A SG 10201704616SA SG 10201704616S A SG10201704616S A SG 10201704616SA SG 10201704616S A SG10201704616S A SG 10201704616SA SG 10201704616S A SG10201704616S A SG 10201704616SA
Authority
SG
Singapore
Prior art keywords
compositions
methods
cell signaling
modulating cell
modulating
Prior art date
Application number
SG10201704616SA
Inventor
Timothy Alan Springer
Leonard Ira Zon
Nagesh K Mahanthappa
Original Assignee
Scholar Rock Inc
Children’S Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc, Children’S Medical Center Corp filed Critical Scholar Rock Inc
Publication of SG10201704616SA publication Critical patent/SG10201704616SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201704616SA 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling SG10201704616SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722969P 2012-11-06 2012-11-06
US201261722919P 2012-11-06 2012-11-06

Publications (1)

Publication Number Publication Date
SG10201704616SA true SG10201704616SA (en) 2017-07-28

Family

ID=50685303

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201704616SA SG10201704616SA (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling
SG11201503271XA SG11201503271XA (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201503271XA SG11201503271XA (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Country Status (10)

Country Link
US (2) US20150284455A1 (en)
EP (1) EP2916867A4 (en)
JP (3) JP2016500704A (en)
AU (3) AU2013341353B2 (en)
CA (2) CA3023553A1 (en)
IL (1) IL238488B (en)
MX (1) MX2015005675A (en)
SG (2) SG10201704616SA (en)
WO (1) WO2014074532A2 (en)
ZA (1) ZA201502884B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (en) 2006-03-31 2021-10-15 中外制药株式会社 Method for regulating antibody hemodynamics
BRPI0817294A2 (en) 2007-09-26 2015-03-17 Chugai Pharmaceutical Co Ltd Method of modifying antibody isoelectric point via amino acid substitution in cdr.
WO2009125825A1 (en) 2008-04-11 2009-10-15 中外製薬株式会社 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
RU2658504C9 (en) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
TW202237660A (en) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
RS61778B1 (en) 2013-05-06 2021-06-30 Scholar Rock Inc Compositions and methods for growth factor modulation
JP7348708B2 (en) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Combination vaccine device and method for killing cancer cells
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
DK3218005T5 (en) 2014-11-12 2024-10-14 Seagen Inc GLYCAN INTERACTING COMPOUNDS AND METHODS OF USING
EA201791253A1 (en) * 2014-12-19 2018-04-30 Чугаи Сейяку Кабусики Кайся ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION
CA2973978A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
EA201791754A1 (en) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся ANTIBODIES CONTAINING ANTIGEN-BINDING DOMAIN DEPENDING ON THE CONCENTRATION OF IONS, Fc-AREA OPTIONS, IL-8-CONNECTING ANTIBODIES AND THEIR APPLICATIONS
WO2017015622A2 (en) * 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof
SI3350220T1 (en) 2015-09-15 2021-12-31 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
CN115869398A (en) * 2015-09-24 2023-03-31 第一三共株式会社 anti-GARP antibodies
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US10287345B2 (en) 2016-01-08 2019-05-14 Scholar Rock, Inc. Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
EP4169942A1 (en) 2016-03-11 2023-04-26 Scholar Rock, Inc. Tgfbeta1-binding immunoglobulins and use thereof
WO2017173278A1 (en) * 2016-03-31 2017-10-05 Asieris Pharmaceutical Technologies Co., Ltd. Combinational uses of nitroxoline and its analogues with chemotherapeis and immunotherapies in the treatment of cancers
LT3368069T (en) 2016-06-13 2020-12-10 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
CA3030427A1 (en) 2016-07-13 2018-01-18 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
KR102102734B1 (en) 2016-08-05 2020-04-22 추가이 세이야쿠 가부시키가이샤 Composition for the treatment or prevention of IL-8 related diseases
WO2018053234A1 (en) * 2016-09-15 2018-03-22 Acceleron Pharma, Inc. Twisted gastrulation polypeptides and uses thereof
JP7198757B2 (en) 2017-01-06 2023-01-04 スカラー ロック インコーポレイテッド Methods for treating metabolic disorders by inhibiting myostatin activation
JP7303182B2 (en) 2017-04-21 2023-07-04 メリタス エルエルシー Methods and antibodies for diabetes-related applications
JP2020519579A (en) 2017-05-09 2020-07-02 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． LRRC33 inhibitors and uses thereof
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
EP4019046A1 (en) 2018-07-11 2022-06-29 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
KR20210121174A (en) 2019-01-30 2021-10-07 스칼러 락, 인크. LTBP complex-specific inhibitors of TGFβ and uses thereof
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
US20220308072A1 (en) 2019-08-12 2022-09-29 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
PH12022550435A1 (en) 2019-08-28 2022-12-19 Chugai Seiyaku Kk Cross-species anti-latent tgf-beta 1 antibodies and methods of use
CN111474336B (en) * 2020-03-21 2023-07-28 南昌大学 A preparation method of nickel ferricyanide nanoparticle chemiluminescent aptasensor and a method for detecting 8-OhdG based on it
WO2022099093A1 (en) * 2020-11-06 2022-05-12 President And Fellows Of Harvard College Scaffolds for enhancing neutrophils and uses thereof
WO2022132666A1 (en) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
CN113061575B (en) * 2021-03-25 2023-04-07 中国人民解放军陆军军医大学 Method for separating and purifying inherent lymphoid cells from colon inherent layer of old mouse
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
CN115286701A (en) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 A target for regulating intestinal mucosal homeostasis or inflammatory bowel disease in mammals and its application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
JP3452946B2 (en) * 1992-02-19 2003-10-06 協和醗酵工業株式会社 Anti-TGF-β masking protein monoclonal antibody
AU5587094A (en) * 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
DK0968723T3 (en) * 1994-03-29 2009-11-09 Renovo Ltd Wound healing or healing of fibrotic disorders using at least one agent against a growth factor
US5616561A (en) * 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO2005013915A2 (en) * 2003-08-08 2005-02-17 The Regents Of The University Of California Novel indications for transforming growth factor-beta regulators
WO2006106599A1 (en) * 2005-03-01 2006-10-12 Kyoto University Pharmaceutical for preventing and/or treating disease caused by abnormal enhancement of extracellular domain shedding
EP2862867A3 (en) * 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
US8236527B2 (en) * 2008-03-14 2012-08-07 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
GB0809592D0 (en) * 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials

Also Published As

Publication number Publication date
CA2890733A1 (en) 2014-05-15
AU2019264599A1 (en) 2019-12-05
US20150284455A1 (en) 2015-10-08
AU2017203805A1 (en) 2017-06-22
EP2916867A4 (en) 2016-10-05
JP2016500704A (en) 2016-01-14
IL238488A0 (en) 2015-06-30
JP2017132796A (en) 2017-08-03
MX2015005675A (en) 2016-02-03
WO2014074532A2 (en) 2014-05-15
CA3023553A1 (en) 2014-05-15
ZA201502884B (en) 2016-01-27
EP2916867A2 (en) 2015-09-16
AU2013341353B2 (en) 2017-03-16
AU2013341353A1 (en) 2015-05-28
WO2014074532A3 (en) 2014-06-26
US20200024339A1 (en) 2020-01-23
AU2017203805B2 (en) 2019-08-15
IL238488B (en) 2020-04-30
SG11201503271XA (en) 2015-05-28
JP2019163317A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
ZA201502884B (en) Compositions and methods for modulating cell signaling
HK1211623A1 (en) Cell lines
HK1212597A1 (en) Compositions for modulating c9orf72 expression c90rf72
ZA201409229B (en) Compositions and methods for modulating utrn expression
EP2850184A4 (en) Compositions and methods for modulating gene expression
EP2850183A4 (en) Compositions and methods for modulating gene expression
AP2014008100A0 (en) Compositions and methods for modulating hemoglobingene family expression
IL237156A0 (en) Microcapsule compositions and methods
EP2850189A4 (en) Compositions and methods for modulating gene expression
SG11201408697QA (en) Methods and compositions for natural killer cells
PT2906696T (en) Methods for modulating c9orf72 expression
EP2836212A4 (en) Novel compositions and methods
EP2850182A4 (en) Compositions and methods for modulating atp2a2 expression
ZA201300319B (en) Compositions and methods for modulating the wnt signaling pathway
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2850187A4 (en) Compositions and methods for modulating pten expression
EP2849800A4 (en) Compositions and methods for modulating bdnf expression
HK1205189A1 (en) Methods and compositions for modulating factor vii expression vii
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
HK1220389A1 (en) Methods and compositions for modulating regulatory cell function
GB201222406D0 (en) Gel compositions
HK1210436A1 (en) Novel cell compositions and methods
HK1215197A1 (en) Gel compositions
GB201222405D0 (en) Gel compositions